June 20, 2019
Vaxart to Present at ASM Microbe 2019
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Vaxart
March 27, 2019
Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial
First Oral Norovirus GII.4 Tablet Vaccine Used in Clinical Trial SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company…
March 20, 2019
Vaxart Announces Closing of Registered Direct Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather…
March 19, 2019
Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines…
March 19, 2019
Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
– First Dosing with Norovirus GII.4 Oral Tablet Vaccine Scheduled for Week of March 18 – SOUTH SAN FRANCISCO, Calif.–(BUSINESS…